Initiates Coverage on Can-Fite BioPharma (NYSE:CANF)

Analysts at assumed coverage on shares of Can-Fite BioPharma (NYSE:CANFGet Rating) in a report released on Wednesday. The firm set a “sell” rating on the stock.

Can-Fite BioPharma stock opened at $0.87 on Wednesday. The firm has a market cap of $23.75 million, a price-to-earnings ratio of -1.32 and a beta of 1.86. Can-Fite BioPharma has a 1 year low of $0.78 and a 1 year high of $2.60. The stock’s 50-day moving average is $0.94.

Can-Fite BioPharma (NYSE:CANFGet Rating) last posted its earnings results on Thursday, May 26th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.03. The company had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.20 million. Can-Fite BioPharma had a negative return on equity of 132.72% and a negative net margin of 1,447.36%. As a group, sell-side analysts anticipate that Can-Fite BioPharma will post -0.42 earnings per share for the current fiscal year.

Can-Fite BioPharma Company Profile (Get Rating)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.

Featured Stories

Want More Great Investing Ideas?

Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with's FREE daily email newsletter.